Based on study senior author Dr. Soeren Mattke, “Addressing the capability constraints may grow to be as challenging as developing very effective treatments for Alzheimer’s.”

WEDNESDAY, November. 15, 2017 (HealthDay News) — Even when researchers were to locate a groundbreaking new strategy to Alzheimer’s, huge numbers of people may not take advantage of it, new information reveals.

That is because the U.S. healthcare system does not be capable of rapidly implement a recently approved treatment on the prevalent scale, based on a study in the RAND Corporation.

An believed 5.5 million Americans are presently coping with Alzheimer’s. By 2040, time is anticipated to leap to 11.six million, based on the study authors.

For example, if your new therapy were approved to be used by 2020 and screening started in 2019, about 71 million Americans aged 55 and older will have to be screened for mild cognitive impairment, they stated. Follow-up exams and imaging tests would not be required to confirm an Alzheimer’s diagnosis. The research authors believed that 2.4 million people could be suggested for that new treatment.

“While there’s no certainty an Alzheimer’s therapy is going to be approved soon, our work shows that healthcare leaders must start thinking on how to react to this type of breakthrough,” Liu described inside a RAND news release.

A minimum of 10 therapies presently undergoing numerous studies are thought promising, based on the study authors. RAND researchers believe enough progress has been created to point out that the possible treatment to slow the results from the disease might be available inside a couple of years.

Leave a Comment

Your email address will not be published. Required fields are marked *